Home
Categories
EXPLORE
True Crime
Comedy
Business
Society & Culture
Sports
History
Fiction
About Us
Contact Us
Copyright
© 2024 PodJoint
00:00 / 00:00
Sign in

or

Don't have an account?
Sign up
Forgot password
https://is1-ssl.mzstatic.com/image/thumb/Podcasts122/v4/4c/de/4e/4cde4e40-9b50-eb5a-a7dc-6d0349265d21/mza_8488596380753874198.jpg/600x600bb.jpg
EXCEL 2.2 Podcast
Lupin, India
14 episodes
1 day ago
Listen to Endocrinologist and Diabetologist discuss the benefits of Empagliflozin & Linagliptin usage in T2D management. This discussion will help clinicians to make informed decisions regarding the management of T2D using novel therapy of Empagliflozin & Linagliptin.
Show more...
Medicine
Health & Fitness
RSS
All content for EXCEL 2.2 Podcast is the property of Lupin, India and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Listen to Endocrinologist and Diabetologist discuss the benefits of Empagliflozin & Linagliptin usage in T2D management. This discussion will help clinicians to make informed decisions regarding the management of T2D using novel therapy of Empagliflozin & Linagliptin.
Show more...
Medicine
Health & Fitness
https://d3t3ozftmdmh3i.cloudfront.net/production/podcast_uploaded_episode/23958957/23958957-1664541763792-ebaec6a162cff.jpg
Timely and optimal glycemic control with Empagliflozin and Linagliptin combination in T2DM management | Dr. Praveen Shankar & Dr. Ajoy Biswas
EXCEL 2.2 Podcast
22 minutes 49 seconds
3 years ago
Timely and optimal glycemic control with Empagliflozin and Linagliptin combination in T2DM management | Dr. Praveen Shankar & Dr. Ajoy Biswas

Timely and optimal glycemic control with Empagliflozin and Linagliptin combination in T2DM management

EXCEL 2.2 Podcast
Listen to Endocrinologist and Diabetologist discuss the benefits of Empagliflozin & Linagliptin usage in T2D management. This discussion will help clinicians to make informed decisions regarding the management of T2D using novel therapy of Empagliflozin & Linagliptin.